🔍

Novelix Pharmaceuticals Ltd (536565)

📊 BSE: 536565 🏢 Healthcare Research, Analytics & Technology 📢 Latest filing: 31 Aug 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Novelix Pharmaceuticals' revenue was ₹36.9 Cr (+65.2% year on year, +46.5% on the previous quarter), and net profit ₹1.2 Cr (+971.7% year on year); the operating margin was 3.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹36.9	+65.2%	+46.5%
Operating profit	₹1.3	+621.9%	+1.5%
Net profit	₹1.2	+971.7%	+29.5%
EPS (₹)	0.49	+444.4%	+14.0%
Operating margin	3.5%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Novelix Pharmaceuticals Schedules 32nd AGM on September 30, 2026; Cut-Off Date September 23

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Aug 2026, 12:37 PM

Novelix Pharmaceuticals Ltd has scheduled its 32nd Annual General Meeting (AGM) for Wednesday, September 30, 2026, at 3:00 PM IST via Video Conferencing. The company has fixed September 23, 2026, as the cut-off date to determine shareholder eligibility for remote e-voting. Remote e-voting will run from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM). The share transfer books and register of members will remain closed from September 24 to September 30, 2026.

32nd AGM scheduled for September 30, 2026 at 03:00 PM via Video Conferencing
Cut-off date for e-voting eligibility set as September 23, 2026
Remote e-voting window open from September 27, 2026 (09:00 AM) to September 29, 2026 (05:00 PM)
Book closure period runs from September 24, 2026 to September 30, 2026

💡 Shareholders holding shares on the cut-off date (September 23, 2026) can participate in remote e-voting and review the AGM notice/annual report for any strategic updates.

Novelix Appoints Gnana Prakash Gattu as Whole-Time Director for a 5-Year Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 31 Aug 2026, 12:34 PM

Novelix Pharmaceuticals Limited has approved the appointment of Mr. Gnana Prakash Gattu as a Whole-time Director for a 5-year term effective August 29, 2026, subject to shareholder approval at the ensuing AGM. Mr. Gattu belongs to the promoter group and brings over 25 years of experience in management and information technology. The appointment formalizes leadership at the executive level as the micro-cap company navigates a TTM revenue base of Rs 4 Cr and TTM net losses of Rs -3 Cr.

Appointed Mr. Gnana Prakash Gattu as Whole-time Director for a 5-year tenure effective August 29, 2026.
Appointment is subject to shareholder approval at the ensuing Annual General Meeting.
Appointee is an IIT-Chennai graduate with over 25 years of experience in management and IT.
Mr. Gattu belongs to the Promoter and Promoter group of the company.

💡 Monitor shareholder voting on the appointment at the upcoming AGM and watch for any strategic roadmap or business turnaround plans from the executive team.

Novelix Appoints Gnana Prakash Gattu as Whole-Time Director for 5 Years; AGM on Sept 30, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 29 Aug 2026, 06:02 PM

Novelix Pharmaceuticals has scheduled its 32nd Annual General Meeting (AGM) for September 30, 2026, with the voting cut-off date set for September 23, 2026. The Board approved the appointment of Mr. Gnana Prakash Gattu as Whole-time Director for a 5-year term effective August 29, 2026, subject to shareholder approval. Mr. Gattu belongs to the promoter group and brings over 25 years of IT and management experience. Register of members will remain closed from September 24 to September 30, 2026.

Gnana Prakash Gattu appointed as Whole-time Director for a 5-year term starting August 29, 2026.
32nd Annual General Meeting convened for September 30, 2026, at 03:00 PM via Video Conferencing.
E-voting cut-off date fixed as September 23, 2026; book closure from September 24 to September 30, 2026.
Appointed M/s. Bharat Khaniwal & Co., PCS, as the scrutinizer for the AGM e-voting process.

💡 Monitor voting outcomes on AGM resolutions on September 30, 2026, and observe if executive leadership changes help address ongoing operational losses.

Novelix Pharma Board to Meet on Aug 29, 2026 for 32nd AGM Notice & WTD Appointment

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 25 Aug 2026, 06:08 PM

Novelix Pharmaceuticals has scheduled a meeting of its Board of Directors on Saturday, August 29, 2026. The primary agenda items include approving the notice and schedule for the company's 32nd Annual General Meeting (AGM) and approving the Board Report for the financial year ended March 31, 2026. The board will also consider appointing a scrutinizer for remote e-voting and evaluate the appointment of Mr. Gnana Prakash Gattu as Whole Time Director. This is a standard corporate compliance and administrative update.

Board meeting scheduled for Saturday, August 29, 2026
To consider and approve the Notice for the 32nd Annual General Meeting
To approve the Board Report for the financial year ended March 31, 2026
Proposal to consider appointment of Mr. Gnana Prakash Gattu (DIN: 00517921) as Whole Time Director

💡 Monitor the outcome of the August 29, 2026 board meeting for final AGM dates and confirmation of executive management appointments.

Novelix Pharmaceuticals Leases 0.925 Acres for Micro Algae & Glass Reactor Facilities

🟡 NEUTRAL ⭐ 3/10

EXPANSION 📅 20 Aug 2026, 01:21 PM

Novelix Pharmaceuticals has entered into a 5-year lease agreement for approximately 0.925 acres (37 Guntas) of land in Siddipet District, Telangana. The site is intended for setting up micro algae cultivation and glass reactor systems. The land is leased from Mr. Gnana Prakash Gattu, a Non-Executive Director and promoter group member, at a monthly rent of Rs 5,000 plus taxes, escalating 5% every three years. Given the annual rental cost of Rs 60,000 against TTM revenue of Rs 4 Cr, the immediate financial commitment is nominal.

Leased 37 Guntas (approx. 0.925 Acres) in Markook Village, Siddipet District, Telangana
5-year lease term effective from 19th August 2026
Monthly rental of Rs 5,000 plus taxes, with a 5% increase every three years
Purpose: Establish facilities for Micro Algae Cultivation and Glass Reactor Systems
Related-party transaction executed with Non-Executive Director & promoter group member Gnana Prakash Gattu

💡 Monitor upcoming quarterly updates for project capex allocations, commissioning timelines, and commercialization milestones for the micro algae setup.

Rs 4.21 Cr Funds Fully Utilized with Zero Deviation for Q1 FY27

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Aug 2026, 06:49 PM

Novelix Pharmaceuticals has reported zero deviation in the utilization of funds raised for the quarter ended June 30, 2026. The company had allocated Rs 421.50 Lakhs (approximately Rs 4.22 Cr) for long-term funding, working capital, and general corporate purposes. The entire amount of Rs 421.50 Lakhs has been utilized as per the original objects. This fundraise is significant as it represents approximately 105% of the company's TTM revenue of Rs 4 Cr.

Total funds allocated for working capital and corporate purposes: Rs 421.50 Lakhs
Total funds utilized as of June 30, 2026: Rs 421.50 Lakhs
Amount of deviation or variation reported for the quarter: Nil
Fundraise magnitude relative to TTM revenue: ~105%
The statement was reviewed and approved by the Audit Committee on August 13, 2026

💡 Monitor upcoming quarterly results to see if the full utilization of these funds (Rs 4.22 Cr) leads to a recovery in revenue and operating margins, which are currently at -66.8%.

Rs 36.91 Cr Revenue: Novelix Pharmaceuticals Reports 65% YoY Revenue Growth in Q1 FY27

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 06:38 PM

Novelix Pharmaceuticals (formerly Trimurthi Ltd) reported a significant scale-up in operations for Q1 FY27, with revenue reaching Rs 36.91 Cr, a 65% increase from Rs 22.35 Cr in the same quarter last year. Net profit surged to Rs 1.18 Cr from a low base of Rs 0.11 Cr YoY, reflecting the company's transition into the API (Bulk Drugs) segment. While the top-line growth is substantial, the business remains a low-margin operation with total expenses accounting for 97% of revenue. The company's paid-up equity capital also increased to Rs 23.90 Cr during the quarter.

Revenue from operations grew 65.1% YoY to Rs 36.91 Cr from Rs 22.35 Cr.
Net profit increased more than 10-fold to Rs 1.18 Cr compared to Rs 0.11 Cr in the year-ago period.
Purchases of stock-in-trade remained the largest cost component at Rs 31.93 Cr, indicating a trading-heavy model.
Paid-up equity share capital increased to Rs 23.90 Cr from Rs 21.09 Cr in the preceding quarter.
The company has fully transitioned to a single business segment: Manufacturing and Trading of APIs.

💡 Investors should monitor if the company can maintain this higher revenue run-rate and whether it can improve its thin net margins, which currently stand at approximately 3.2%.

₹1.18 Cr Net Profit in Q1 FY27; Revenue Jumps 65% YoY to ₹36.91 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 06:12 PM

Novelix Pharmaceuticals (formerly Trimurthi Ltd) reported a strong start to FY27 with Q1 revenue reaching ₹36.91 Cr, a 65% increase from ₹22.35 Cr in the same quarter last year. Net profit surged to ₹1.18 Cr from a marginal ₹0.11 Cr YoY, reflecting the company's pivot into API manufacturing and trading. Paid-up equity capital increased to ₹23.90 Cr from ₹21.09 Cr in the preceding quarter, suggesting recent capital infusion. Despite the top-line growth, operating margins remain thin at approximately 3% due to high trading/purchase costs.

Revenue from operations grew 65.1% YoY to ₹36.91 Cr from ₹22.35 Cr.
Net profit increased more than 10-fold to ₹1.18 Cr compared to ₹0.11 Cr in Q1 FY26.
Paid-up equity share capital rose to ₹23.90 Cr from ₹21.09 Cr as of March 31, 2026.
Purchases of stock-in-trade accounted for ₹31.93 Cr, representing 86.5% of total revenue.
Earnings Per Share (EPS) improved to ₹0.49 from ₹0.09 in the year-ago period.

💡 Monitor the sustainability of this higher revenue run-rate and whether the company can improve its thin operating margins as it transitions from trading to manufacturing APIs.

Aug 13 Board Meeting to Approve Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 09 Aug 2026, 07:18 PM

Novelix Pharmaceuticals has scheduled a board meeting for August 13, 2026, to approve unaudited standalone financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of ₹70 Cr and is currently loss-making with a TTM PAT of -₹3 Cr. Investors should note the recent increase in promoter holding from 49.43% in March 2026 to 54.29% in July 2026. The trading window for designated persons has been closed since July 1, 2026, and will remain so until 48 hours after the results are declared.

Board meeting scheduled for August 13, 2026, to approve Q1 results
Financial results pertain to the quarter ended June 30, 2026
Trading window closed from July 01, 2026, until 48 hours post-meeting
Company TTM revenue is ₹4 Cr against a market cap of ₹70 Cr
Promoter holding increased to 54.29% as of July 2026

💡 Monitor the financial results on August 13 to check for any improvement in operating margins, which were -66.8% on a TTM basis.

100,000 Shares Allotted to Promoter Group via Warrant Conversion

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 13 Jul 2026, 07:41 PM

Novelix Pharmaceuticals has allotted 100,000 equity shares to Neha Gattu, a member of the promoter group, following the conversion of warrants on July 9, 2026. This transaction increased the total promoter group holding from 500,000 to 600,000 shares. Concurrently, the company's total equity base expanded significantly from 23.89 million to 28.47 million shares. Consequently, the promoter group's stake marginally increased from 2.09% to 2.11% of the expanded capital.

100,000 equity shares allotted to Neha Gattu on July 9, 2026, via warrant conversion.
Total promoter group holding (including PACs) increased to 600,000 shares.
Company's total equity share capital expanded by 4,575,000 shares to reach 28,470,000 shares.
Promoter group stake stands at 2.11% post-allotment, up from 2.09%.
The conversion was part of a preferential allotment basis previously approved.

💡 Investors should monitor the utilization of the capital raised from this warrant conversion and observe if further dilutions occur as the remaining warrants are converted.

100,000 Equity Shares Allotted to Promoter Group via Warrant Conversion

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 13 Jul 2026, 07:32 PM

Neha Gattu, a member of the promoter group, was allotted 100,000 equity shares on July 9, 2026, following the conversion of warrants issued on a preferential basis. This transaction is part of a broader capital expansion that saw the company's total equity base increase from 23.89 million to 28.47 million shares. The combined holding of the three disclosed promoter group members (Gattu Gnana Prakash, Arati Gattu, and Neha Gattu) now stands at 600,000 shares, representing 2.11% of the expanded capital. This move indicates promoter participation in the company's capital infusion strategy.

Allotment of 100,000 equity shares to Neha Gattu on July 9, 2026, through warrant conversion.
Total equity capital expanded by 4,575,000 shares, increasing from 23,895,000 to 28,470,000 shares.
Combined promoter group holding for the specified individuals increased to 600,000 shares (2.11%).
The company had 3,375,000 outstanding convertible warrants prior to this specific allotment phase.

💡 Monitor the utilization of funds raised through this preferential allotment and watch for further warrant conversions by other promoter group members.

100,000 Shares Allotted to Promoter Group via Warrant Conversion

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 13 Jul 2026, 07:30 PM

Neha Gattu, a member of the promoter group, was allotted 100,000 equity shares on July 9, 2026, following the conversion of warrants issued through a preferential allotment. This transaction increased the total promoter group (Gattu family) holding to 600,000 shares. Concurrently, the company's total equity capital expanded significantly from 23.89 million shares to 28.47 million shares, indicating other allotments or conversions occurred in the same period. The promoter group's post-acquisition stake stands at 2.11% of the expanded capital.

100,000 equity shares allotted to Neha Gattu on July 9, 2026, via warrant conversion
Total promoter group holding (Gattu family) reached 600,000 shares
Company's total equity capital increased by 4,575,000 shares to reach 28,470,000 shares
Post-acquisition promoter group stake is 2.11% of the diluted capital
Warrants were originally issued on a preferential allotment basis

💡 Investors should monitor the company's upcoming financial results to see how the capital raised from this preferential allotment is being utilized for business growth.

1,00,000 Shares Acquired by Promoter Group via Warrant Conversion

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 13 Jul 2026, 06:39 PM

Novelix Pharmaceuticals reported that promoter group entity Srinidhi Fine Chemicals LLP acquired 1,00,000 equity shares on July 11, 2026. This acquisition occurred through the conversion of warrants previously issued on a preferential basis. Consequently, the entity's stake in the company rose from 1.23% to 2.47%. This transaction reflects a doubling of the entity's holding and provides a positive signal regarding promoter commitment.

Acquisition of 1,00,000 equity shares by Srinidhi Fine Chemicals LLP
Promoter group entity stake increased from 1.23% to 2.47%
Shares were allotted on July 11, 2026, following warrant conversion
Total post-acquisition holding for this specific entity stands at 2,00,000 shares

💡 Investors should monitor the total number of outstanding warrants to assess potential future equity dilution and the total capital infusion expected from conversions.

100,000 Shares Allotted to Promoter Group via Warrant Conversion

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 13 Jul 2026, 01:05 PM

Neha Gattu, a member of the Promoter Group, was allotted 100,000 equity shares on July 9, 2026, following the conversion of warrants issued through a preferential allotment. This transaction increased the total promoter group holding from 500,000 to 600,000 shares. Concurrently, the company's total equity share capital expanded significantly from 23,895,000 to 28,470,000 shares, indicating broader capital infusion or other warrant conversions. The promoter group's stake now stands at 2.11% of the expanded capital.

100,000 equity shares allotted to Neha Gattu (Promoter Group) on July 9, 2026
Promoter group total holding increased from 500,000 to 600,000 shares
Total equity share capital increased by approximately 19% to 28,470,000 shares
Promoter group percentage holding adjusted to 2.11% post-allotment
Conversion price based on earlier preferential allotment terms (face value Rs 10)

💡 Investors should monitor the company's upcoming financial results to see how the capital raised from this preferential allotment is being deployed and its impact on earnings per share (EPS) due to the 19% equity dilution.

View All 536565 Announcements on Live Market Tracking →